EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024

Elisabetta Degasperi iD, Lisa Sandmann iD, Heiner Wedemeyer iD, Pietro Lampertico iD, Delta Cure 2024 Working Group

Liver International · 2025-07 · 45 (7)

DOI: 10.1111/liv.70189 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 20.06.2025. Verfasst von Elisabetta Degasperi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis Delta Virus, Hepatitis D, Chronic, Hepatitis D. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic infection with hepatitis delta virus (HDV) leads to rapid progression of liver disease, cirrhosis and complications such as end‐stage liver disease and hepatocellular carcinoma. In recent years, understanding of the HDV life cycle has increased significantly; however, much remains unknown about the pathogenesis, host‐virus interactions and the role of the immune system in HDV persistence and control. Challenges remain in the diagnosis of HDV, not only because of the lack of standardised assays, but also because of limited access and availability in resource‐limited countries. The improved knowledge of the HDV life cycle has led to the development and approval of the first HDV‐direct antiviral, Bulevirtide (BLV). Treatment with BLV shows high rates of viral suppression in clinical trials and real‐world studies. Questions remain about the duration of treatment with BLV and the potential benefits of combination therapy with pegylated interferon alpha (PegIFNα). First data from the Phase III study in which BLV was stopped after 3 years of treatment have recently been presented at congresses. Results from the Phase II study evaluating the combination of BLV and PegIFNα, as well as real‐world experiences, have been published. Despite recent advances in antiviral treatment, strategies to achieve HBsAg loss, which most closely resembles HDV cure, are not available and antiviral treatment for patients with advanced liver disease is limited. The third international Delta Cure meeting, held in Milan in October 2024, aimed to share the latest findings, and this review highlights key takeaways from the lectures and research on HDV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis Delta VirusHepatitis D, ChronicHepatitis DHumansInterferon-alphaDrug Therapy, CombinationNucleic AcidsPolymers

Stichwörter der Autor:innen

BulevirtideDelta CureHDVHDV RNAchronic Hepatitis Deltacirrhosisentry inhibitorlonafarnib

Substanzen

Antiviral AgentsInterferon-alphaREP 2139Nucleic AcidsPolymers

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • D-SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917), Hannover, Germany.
  • Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Excellence Cluster RESIST, Excellence Initiative Hannover Medical School, Hannover, Germany.
  • German Center for Infection Research (DZIF), Braunschweig, Germany.
  • Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy.

ORCID-Profile: Elisabetta Degasperi, Lisa Sandmann, Heiner Wedemeyer, Pietro Lampertico

Förderung

  • NIAID NIH HHS

Zitieren

APA

Degasperi, E., Sandmann, L., Wedemeyer, H., Lampertico, P., & Delta Cure 2024 Working Group (2025). Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024. Liver International, 45(7). https://doi.org/10.1111/liv.70189

Vancouver

Degasperi E, Sandmann L, Wedemeyer H, Lampertico P, Delta Cure 2024 Working Group. Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024. Liver International. 2025;45(7). doi:10.1111/liv.70189

BibTeX
@article{Degasperi2025,
  author = {Degasperi, Elisabetta and Sandmann, Lisa and Wedemeyer, Heiner and Lampertico, Pietro and Delta Cure 2024 Working Group, Delta Cure 2024 Working Group},
  title = {Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {7},
  doi = {10.1111/liv.70189}
}
Kostenlos starten →